Findings Part News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

/PRNewswire/ Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today.

United statesUnited kingdomSouth koreaRepublic of koreaSamuel klempnerDouglase onsiCynthia sirardMatthew deyoungSamuelj klempnerNovarock biotherapeuticsProfessor at harvard medical schoolBeigene ltdAmerican society of clinical oncologyDrug administrationHarvard medical schoolLeap therapeutics inc

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSouth koreaRepublic of koreaDouglase onsiSamuel klempnerNovarock biotherapeuticsMatthew deyoungCynthia sirardProfessor at harvard medical schoolDrug administrationBeigene ltdAmerican society of clinical oncologyHarvard medical schoolLeap therapeutics incLeap therapeutics

Valo Health - FDA Collaborative Study in Human Cardiac Tissues Demonstrates Potential to Predict Clinical Efficacy of Cardiac Contractility Modulation Devices to Treat Heart Failure

/PRNewswire/ Valo Health, Inc ("Valo") shared the initial results of a collaborative study with the U.S. Food and Drug Administration (FDA), demonstrating.

New yorkUnited statesSan franciscoJennifer hanleyMichaelp grazianoValo biowireGraeme bellYear research collaboration between valoDrug administrationValo health incValo healthFindings partFive year research collaboration between valoCardiac contractility modulationTranslational biologyOpal computational